A young person reading glowing digital brain scan on tablet surrounded by animated psilocybin mushrooms and serotonin graphics, visualizing anti-anxiety effects of psychedelics without hallucinations

⬇️ Prefer to listen instead? ⬇️


  • A 2024 study shows specific brain circuits activated by psychedelics can reproduce anti-anxiety effects without hallucinations.
  • Activating tagged neurons in the medial prefrontal cortex reduced anxiety in mice without administering any drug.
  • Blocking serotonin receptors stopped both psychedelic effects and the benefit of reactivating neural circuits.
  • Findings suggest it's possible to isolate the anti-anxiety effects of psilocybin from its hallucinogenic experience.
  • Research may lead to non-hallucinogenic psychedelics or neurotechnologies that mimic therapeutic brain activity.

Natural psilocybin mushrooms arranged on wooden surface

The Future of Psychedelics for Anxiety: Healing Without the Hallucinations

In recent years, there's been growing scientific and public interest in using psychedelics for anxiety and depression. Research has shown that compounds like psilocybin, the active ingredient in magic mushrooms, can produce rapid and long-lasting mental health benefits. But hallucinations and altered consciousness have made these treatments controversial and logistically challenging. But a new study offers a different idea. It suggests we might be able to activate the same brain circuits psychedelics affect, giving anxiety relief without the "trip."


The Rise of Psychedelics for Anxiety and Depression

Psychedelics are starting to be used in medicine again. This is after being looked down on and banned for decades. Over the past ten years, many clinical trials have shown the potential of compounds like psilocybin, LSD, and MDMA for treating various mental health conditions. Among these, using psychedelics for anxiety and depression has shown some of the most interesting results.

In several clinical settings, psilocybin has shown significant and lasting reductions in symptoms of depression and anxiety. For instance, studies with terminally ill patients show that one guided psilocybin session can greatly reduce distress about life and fear of death. This can last for months. For those suffering from PTSD or treatment-resistant depression, psilocybin offers a fast-acting alternative to traditional selective serotonin reuptake inhibitors (SSRIs), which can take weeks or even months to show effects—and often don’t work for everyone.

This growing body of evidence has led to psilocybin being granted Breakthrough Therapy status by the FDA for treatment-resistant depression. But there is still something that stops it from being used widely: the hallucinogenic experience that is part of classical psychedelics.

While some participants describe these experiences as among the most meaningful of their lives, others may find them unsettling or disorienting. Moreover, for doctors and clinics, making a patient go through hours-long supervised sessions with strong changes in what they sense is costly, takes a lot of time, and doesn't work for all mental health care systems.


Brain imaging scan display in neuroscience research lab

A New Perspective: Can We Separate the Healing from the Hallucination?

In light of these challenges, researchers have started looking at whether we can keep the healing effects of psychedelics while getting rid of or reducing the hallucination part. Doing this would not only make therapy with psychedelics easier to get, but could also help lower the bad reputation and rules that make using these compounds hard. A recent study published in Science takes an important step in this direction.

It doesn’t try to change psilocybin chemically or make a new compound like it that doesn’t cause hallucinations. Instead, it focuses on the brain areas psychedelics activate and asks a question about the brain: Can we directly aim for the brain circuits that cause psilocybin's anti-anxiety effects without needing any drug?


Human brain model with illuminated prefrontal cortex

How Psychedelics Affect Brain Circuits and Depression

To understand how this works, it's important to understand how psychedelics and brain circuits are linked—especially regarding mood disorders like depression. The anti-anxiety effects of psilocybin and related compounds are largely thought to come from changes in activity inside the medial prefrontal cortex (mPFC), amygdala, and other areas involved in controlling emotions.

Psilocybin works by acting on the serotonin 2A receptor (5-HT2A), which is found a lot in these brain regions. Activating these receptors seems to "reset" brain patterns that don't work well and cause depression and anxiety. Neuroimaging studies show more connections between different brain regions when someone is under the influence of psychedelics. This suggests these substances might help fix brain networks that aren't working right and are linked to mental illness.

But the big question is whether these good changes need the psychedelic experience. Or do they just happen because the receptors are activated and brain circuits change? And could we get those changes in other ways?


Researcher analyzing mouse brain for anxiety study

Study Spotlight: Bypassing the Trip with Brain Circuit Activation

The Science study looked at this idea using mice. They gave mice a standard psychedelic compound called DOI. It affects the same 5-HT2A receptors as psilocybin. Then they measured changes in how the mice acted and how their brains worked.

Mice that got DOI not only showed less anxiety, but their lower anxiety lasted even after the visible signs of hallucination (measured by head twitches) were gone. This led to a key question: Can scientists isolate and reactivate the specific neurons involved in reducing anxiety, long after the psychedelic compound has left the body?

The answer was yes. They used tools like optogenetics.


Detailed rendering of medial prefrontal cortex activation

Zeroing In on the Medial Prefrontal Cortex

The medial prefrontal cortex (mPFC) turned out to be very important in this. This brain region is very important for controlling emotions, making decisions, and understanding social things. These are often not working right in mood and anxiety disorders. fMRI scans in human studies have also shown that the mPFC is one of the areas that react the most during psychedelic experiences.

Using mice changed by genetics so they had light-sensitive neurons, the researchers could watch and control how neurons in the mPFC acted. They discovered that nearly half of the neurons in this area became activated following a single dose of DOI.

By marking and then turning on only the neurons that had “lit up” during the DOI treatment, the researchers could basically bring back the drug's anti-anxiety effect without giving the mice another dose.


Mouse on elevated plus maze during behavioral study

Behavioral Testing: Measuring Anxiety in Mice Models

To make sure these findings mattered for how the mice acted, researchers used two well-known ways to test for anxiety

  • Marble Burying Test: Mice naturally tend to bury objects like marbles because they are instinctively anxious. A calmer mouse buries fewer marbles.
  • Elevated Plus Maze: This cross-shaped device has both open and closed arms. Anxious mice stay out of the open areas, while more relaxed mice go into them.

Mice that got DOI buried fewer marbles and spent more time in the open arms. This showed they had less anxiety. When scientists used optogenetics to turn on specific neurons in the mPFC one day later—without giving the mice any more drug—they saw the same changes in how the mice acted.

Importantly, the head-twitch response—a marker of hallucination-like activity—did not return during this reactivation. This clearly separated the hallucinogenic effects from the lasting therapeutic benefits.


Serotonin molecules interacting in human brain model

Molecular Insights: The Role of Serotonin Receptors

Interestingly, not all neurons activated by DOI directly had the serotonin 2A receptor. But when the receptor was blocked before giving the psychedelic, none of the good effects that happen later occurred. This was true during the first treatment and after turning on the marked neurons with optogenetics.

This shows that turning on serotonin receptors at first is needed to start the good changes in brain circuits. And these changes can later be “replayed” without using the drug again. The anti-anxiety effects of psilocybin and similar compounds appear to be stored in brain circuits—waiting to be reactivated by the right stimulation.

This idea completely changes how we understand psychedelic therapy. Instead of thinking the psychedelic trip is the way it heals, we might now see it as something that starts lasting changes happening across important brain circuits.


Happy Growing! zombiemyco.com

Therapeutic Implications: Non-Hallucinogenic Psychedelics Could Be the Future

This new model supports a good way to make new kinds of psychedelic treatments. By identifying and targeting the specific brain circuitry involved in psilocybin’s anti-anxiety effects, researchers could create

  • Circuit-targeted brain stimulation therapies, like transcranial magnetic stimulation (TMS) or deep-brain stimulation (DBS).
  • Psychedelic-inspired compounds that activate serotonin 2A receptors but do not cause hallucinations.
  • Personalized mental health therapies based on looking closely at a person's brain circuits.

Companies are already developing non-hallucinogenic versions of traditional psychedelics, sometimes called “psychoplastogens.” These help brain cells connect better without changing what people see or hear. The meaning for mental health treatment is huge—less bad reputation, safer, and easier to get.


Medical professional analyzing brain scan for therapy

Psilocybin In the Bigger Picture of Brain-based Therapies

Though this study used DOI in mice, the findings apply broadly to psilocybin. Structurally and pharmacologically, DOI and psilocybin affect overlapping brain systems, especially in the prefrontal cortex and default mode network. This means the anti-anxiety effects of psilocybin likely come from similar brain activations. And they may one day be copied or made stronger by other technologies.

Moreover, these effects connect to wider research linking brain circuits and depression. Recent brain science has shown that conditions like major depressive disorder (MDD) involve activity that isn't normal in networks like the default mode network, salience network, and mPFC. Psychedelics may help reset these networks—basically giving the mind a “reboot.”

Understanding how this works may allow scientists to develop treatments that copy the anti-anxiety effects of psilocybin for different diagnoses without necessarily causing altered states of consciousness.


Whats in the Box? "MINI " Mushroom Grow Bag - 3lb

Mushroom Wellness Culture: Where Science Meets Self-Care

Where mental health and mycology meet, there is a growing movement of people interested in wellness, amateur growers, and researchers. Each is curious about the full potential of mushrooms. From nootropics to growing new brain cells, from taking tiny doses to large doses, mushrooms have started big talks in culture about healing and full self-care.

At Zombie Mushrooms, we believe in combining traditional mushroom growing with the latest brain science. Every grow kit sold is a small step toward understanding more. It's a step toward a place where ancient organisms and modern science come together in your garden or grow tent.

Whether you’re experimenting with legal mushroom varieties or learning about psilocybin policy reform, the future of mental wellness may very well be fungal.


Researcher taking notes on psychedelic mouse study

Limitations and Next Steps for Psychedelic Research

As exciting as this research is, it’s important to remember its limits

  • The study was done in mice. And behavioral tests like marble burying are only stand-ins for human anxiety.
  • DOI, while chemically similar to psilocybin, is not used in clinical settings, and its effects may differ subtly.
  • Optogenetics is a powerful tool, but it’s not yet usable in living humans. Not without procedures that go inside the body.
  • The system used to mark neurons doesn’t catch cells that are slowed down by psychedelics. These cells might also be important for changes in mental health.

More research is needed using human brain models. This is to check which circuits are most active in causing lasting healing effects. And we need to see if turning them on again can be done without going inside the body.


Conclusion: Decoding the Anti-Anxiety Effects of Psilocybin Without the Trip

This new study gives strong proof that the anti-anxiety effects of psychedelics, including psilocybin, may be separated from the effects that cause hallucinations. By focusing on the brain circuits involved instead of the drug experience itself, researchers have opened the door for therapies that are more aimed at specific problems, fit each person, and are easier to get.

We may be starting a time where a person can get the benefits of psychedelics for anxiety—without having to “trip” at all. That would be a big change in how we see these powerful natural compounds. It would make them tools not just for looking inward, but for safe, science-backed mental health healing.


Curious to learn more about the mental health benefits of mushrooms? Check out Zombie Mushrooms’ grow kits and read our science-based content. Join our community and see how fungi are changing wellness for the future—one brain cell at a time.

    Health and wellness

    Leave a comment

    All comments are moderated before being published